ArticleClinical rheumatology2026
CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis.
Ziyi Song et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it